Cogentix Medical Inc  

(Public, NASDAQ:CGNT)   Watch this stock  
Find more results for NASDAQ:VSCI
0.00 (0.01%)
Real-time:   11:43AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.62 - 1.65
52 week 1.42 - 6.20
Open 1.62
Vol / Avg. 4,487.00/46,665.00
Mkt cap 42.56M
P/E     -
Div/yield     -
EPS -2.45
Shares 26.27M
Beta 1.03
Inst. own 7%
Aug 3, 2015
Q1 2016 Cogentix Medical Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 31, 2015
Vision Sciences Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
May 14, 2015
Q4 2015 Cogentix Medical Inc Earnings Call
May 14, 2015
Q4 2015 Cogentix Medical Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2015
Net profit margin -33.23% -29.06%
Operating margin -33.11% -28.83%
EBITD margin - -28.72%
Return on average assets -27.45% -20.82%
Return on average equity -496.69% -42.87%
Employees 105 -
CDP Score - -


5420 Feltl Rd
MINNETONKA, MN 55343-7982
United States - Map
+1-952-4266140 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cogentix Medical, Inc. (Cogentix Medical), formerly Vision-Sciences Inc., is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company's products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Officers and directors

Robert C. Kill Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Brett A. Reynolds Senior Vice President, Chief Financial Officer, Corporate Secretary
Age: 45
Bio & Compensation  - Reuters
Darin Hammers Senior Vice President - Global Sales and Marketing
Bio & Compensation  - Reuters
James P. Stauner Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
Kenneth H. Paulus Director
Age: 55
Bio & Compensation  - Reuters
Cheryl Pegus M.D. Director
Age: 49
Bio & Compensation  - Reuters
Lewis C. Pell Director
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kevin H. Roche Director
Age: 63
Bio & Compensation  - Reuters